Navigation Links
IKARIA(R) to In-License BioLineRx's BL-1040
Date:7/6/2009

CLINTON, N.J. and JERUSALEM, July 6 /PRNewswire/ -- Ikaria Holdings, Inc. and BioLineRx Ltd. (TASE: BLRX) today announced that Ikaria has entered into an agreement to obtain a worldwide exclusive license to BioLineRx's BL-1040, a potential breakthrough treatment for preventing pathological cardiac remodeling following acute myocardial infarction (AMI).

BL-1040, currently in a phase I/II clinical trial, is administered via the coronary artery during standard catheterization and flows into the damaged heart muscle, where it forms a protective "scaffold" that enhances the mechanical strength of the heart muscle during recovery and repair. BL-1040 is the first program to graduate from the BIJ (BioLine Innovations Jerusalem) incubator subsidized by the Israeli Office of the Chief Scientist.

Under the terms of the agreement, BioLineRx will receive upfront and milestone payments. BioLineRx will also receive royalties on annual net sales. Ikaria will be responsible for completing clinical development and commercialization efforts. The deal is contingent upon receipt of the approval of the Israeli Office of the Chief Scientist.

"The acquisition of the rights to BL-1040 reinforces our commitment to deliver novel treatments to critically ill patients around the world," commented Daniel Tasse, President and CEO of Ikaria. "Millions of patients suffer from MI each year, and BL-1040 represents the potential of an exciting solution to the problem of ventricular remodeling following AMI, for which the unmet need remains very high."

"This agreement is consistent with our business model of developing early-stage programs through human Proof of Concept trials and ultimately partnering with a global therapeutics company that has the expertise and resources to complete development and commercialization," said Morris C. Laster, M.D., CEO of BioLineRx. "Ikaria's deep and singular focus on therapies for patients
'/>"/>

SOURCE Ikaria Holdings Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Ikaria(R) to Present at 27th Annual JPMorgan Healthcare Conference
2. Ikaria(R) Strengthens Commercial Operations and Human Resources Leadership
3. Strativa Pharmaceuticals, the Proprietary Products Division of Par Pharmaceutical, Provides an Update on Development Status of Pafuramidine and Other in-Licensed Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... -- MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX) aclinical stage ... antibody, HuMab 5B1, will be garnering major attention as ... World Molecular Imaging Congress (WMIC) being held in ... the Department of Radiology at Memorial Sloan Kettering Cancer ... MabVax,s lead antibody as a PET imaging agent and ...
(Date:8/31/2015)... Aug. 31, 2015  For people with Down syndrome, ... day. The biotechnology company, located in the Science + ... the best potential therapies yet for people with Down syndrome ... Correction of Down syndrome and Edwards syndrome aneuploidies in ... DNA Research . Elixirgen plans to develop this technology ...
(Date:8/31/2015)... FRANCISCO, Calif. , Aug. 31, 2015 ... discovery and development of novel cancer immunotherapies, announced today ... Ph.D., as Chief Executive Officer and William Ho ... and Ho join an experienced management team led by ... Jordan Fridman , Ph.D., Chief Scientific Officer; Jay ...
(Date:8/31/2015)... ... 31, 2015 , ... There’s a new treatment option for excessive menstrual bleeding ... new FDA approved system in the last 14 years, and the only endometrial ablation ... bleeding) rate of 66%, the high Patient Satisfaction rate of 98%, and the fastest ...
Breaking Biology Technology:MabVax Therapeutics HuMab 5B1 Antibody Is Highlighted at Upcoming World Molecular Imaging Congress in Five Separate Presentations 2MabVax Therapeutics HuMab 5B1 Antibody Is Highlighted at Upcoming World Molecular Imaging Congress in Five Separate Presentations 3MabVax Therapeutics HuMab 5B1 Antibody Is Highlighted at Upcoming World Molecular Imaging Congress in Five Separate Presentations 4New Down syndrome therapy discovered 2FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 2FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 3FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 4U.S. FDA Approves Minerva Endometrial Ablation System 2U.S. FDA Approves Minerva Endometrial Ablation System 3
... ... ... ... ...
... ... ... ... ...
... ... ... ... ...
Cached Biology Technology:Zenith Biotech Introducing Novel StemQ(R) Hepatic and Neural Models for Use in Drug Discovery, Metabolism and Toxicology Studies, at The 49th Annual Meeting and ToxExpo In Salt Lake City, Utah, March 7-11, 2010, Booth #136 2Zenith Biotech Introducing Novel StemQ(R) Hepatic and Neural Models for Use in Drug Discovery, Metabolism and Toxicology Studies, at The 49th Annual Meeting and ToxExpo In Salt Lake City, Utah, March 7-11, 2010, Booth #136 3Zenith Biotech Introducing Novel StemQ(R) Hepatic and Neural Models for Use in Drug Discovery, Metabolism and Toxicology Studies, at The 49th Annual Meeting and ToxExpo In Salt Lake City, Utah, March 7-11, 2010, Booth #136 4Zenith Biotech Introducing Novel StemQ(R) Hepatic and Neural Models for Use in Drug Discovery, Metabolism and Toxicology Studies, at The 49th Annual Meeting and ToxExpo In Salt Lake City, Utah, March 7-11, 2010, Booth #136 5Zenith Biotech Introducing Novel StemQ(R) Hepatic and Neural Models for Use in Drug Discovery, Metabolism and Toxicology Studies, at The 49th Annual Meeting and ToxExpo In Salt Lake City, Utah, March 7-11, 2010, Booth #136 6Zenith Biotech Introducing Novel StemQ(R) Hepatic and Neural Models for Use in Drug Discovery, Metabolism and Toxicology Studies, at The 49th Annual Meeting and ToxExpo In Salt Lake City, Utah, March 7-11, 2010, Booth #136 7MO BIO Laboratories, Inc. Launches PowerBiofilm(TM) DNA and RNA Isolation Kits 2MO BIO Laboratories, Inc. Launches PowerBiofilm(TM) DNA and RNA Isolation Kits 3Concord Medical to Report Fourth Quarter and Fiscal Year 2009 Unaudited Financial Results on Thursday, March 18, 2010 2Concord Medical to Report Fourth Quarter and Fiscal Year 2009 Unaudited Financial Results on Thursday, March 18, 2010 3Concord Medical to Report Fourth Quarter and Fiscal Year 2009 Unaudited Financial Results on Thursday, March 18, 2010 4Concord Medical to Report Fourth Quarter and Fiscal Year 2009 Unaudited Financial Results on Thursday, March 18, 2010 5Concord Medical to Report Fourth Quarter and Fiscal Year 2009 Unaudited Financial Results on Thursday, March 18, 2010 6
(Date:8/20/2015)... , Aug. 20, 2015 The ... consumers that are active and healthy. However, wearable ... the hospital environment to help improve diagnostic capabilities ... video from the Wearable Technologies Conference 2015 ... new applications for wearables in healthcare.    ...
(Date:8/18/2015)... Aug. 18, 2015  Navitas today announced ... to the Submission Content Management webinar scheduled ... non-profit forum. Dedicated to the Implementation of Regulatory ... platform for industry, vendors, health authorities, consultants ... work towards a standard method of implementing ...
(Date:8/12/2015)... Florida , August 12, 2015 ... pace of mobile payment innovation and advanced biometrics technology ... replace the way consumers rely on using their credit ... with reinventing the future for payment services led by ... NXTD ), :  Google, Inc. (NASDAQ: GOOG ...
Breaking Biology News(10 mins):Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 2Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 3Navitas, a Key Contributor in IRISS Forum Webinar 2Navitas, a Key Contributor in IRISS Forum Webinar 3Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 2Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 3Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 4Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 5Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 6
... rapidly in water from one water molecule to the next, ... The principle of proton conduction in water has been known ... its discoverer, Theodor Grotthuss. It is based on the assumption ... from one molecule to another; instead, there is cleavage of ...
... a rapid warming in the upper subtropical oceans of ... and preceding cooling trends to ocean circulation changes induced ... in the Northern Hemisphere from human activity. The ... NSW, was published today in Scientific Reports . ...
... MINNEAPOLIS , July 23, 2013 Techne Corporation (NASDAQ: ... Fernando Bazan , Ph.D. has been appointed Chief Technology Officer. ... from structural biology to drug discovery for the treatment of ... and influencing future growth in Techne,s world-wide market. ...
Cached Biology News:Concerted proton hopping in water 2Rapid upper ocean warming linked to declining aerosols 2Techne Corporation Appoints Dr. J. Fernando Bazan As Chief Technology Officer 2
Agarose Gel Loading Dye Mixture 6X...
Pharmalyte, narrow range pH 4.2-4.9, 25 ml. Category: Electrophoresis Systems & Standards & Reagents, Electrophoresis Standards and Reagents, Immobiline for IEF and Carrier Ampholytes....
Rabbit polyclonal to XTP4 ( Abpromise for all tested applications). entrezGeneID: 84299 SwissProtID: Q9BRT3...
...
Biology Products: